Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in unresectable oral squamous cell carcinoma (single-arm exploratory study)
ChiCTR2100046191Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in Oral Mucosal Carcinoma (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Objective remission rate and R0 resection rate. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2100046191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046191.